The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

Johnson & Johnson MedTech announced today that the FDA approved its Varipulse pulsed field ablation (PFA) platform for ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing ...

The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of condition which causes abnormal ...

Johnson & Johnson MedTech division Biosense Webster has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its VARIPULSE Platform, designed to treat ...

In pulsed field ablation, we initiated the commercial launch of the VARIPULSE platform in the EU and Japan receiving early positive physician feedback in the external evaluation period.

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

Also in Cardiovascular, we are preparing for the anticipated approval of VARIPULSE in the U.S. and the submission of Impella ECP for regulatory approval. In Orthopaedics, we launched several ...

November 6, 2024 • Despite Donald Trump’s focus on fossil fuels, his return to the White House won’t derail clean energy, analysts and activists say.

Shares in Boston Scientific (NYSE:BSX) fell more than 1% in premarket trading Friday after analysts at Needham&Co. downgraded the stock to Hold from Buy, citing several concerns about the company's ...